Genentech hopes to see potential improved delivery of Lucentis in eye implant
This article was originally published in Clinica
Executive Summary
Pharma company Genentech is developing an intraocular implant for the delivery of its age-related macular degeneration (AMD) drug Lucentis (ranibizumab) over a longer period, thereby reducing the dosing frequency. Although Genentech has not discussed the strategy behind the move, it is possible that migrating patients onto the device-delivered form of Lucentis could not only be a useful part of life-cycle management for the drug, but might also encourage patients to seek Lucentis, rather than the similar but much cheaper vascular endothelial growth factor inhibitor, Avastin, another Genentech product.